Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study.
Kadokawa Y, Takagi M, Yoshida T, Tatsumi A, Fujita K, Inoue T, Ohe S, Nakai Y, Yamamoto S, Otsuka T, Ishihara R, Isei T, Kumagai T, Nishimura K, Imamura F.
Kadokawa Y, et al. Among authors: tatsumi a.
Mol Clin Oncol. 2021 Apr;14(4):65. doi: 10.3892/mco.2021.2227. Epub 2021 Feb 8.
Mol Clin Oncol. 2021.
PMID: 33680456
Free PMC article.